Status:
TERMINATED
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
Lead Sponsor:
Eli Lilly and Company
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (A...
Eligibility Criteria
Inclusion
- Must be treated with atorvastatin 40 mg/day for at least 30 days prior to screening
- Have an LDL-C \>70 mg/deciliter(dL) or non-HDL-C \>100 mg/dL
- Have screening triglycerides ≤400 mg/dL (≤4.5 millimoles/Liter)
- Individuals with ASCVD and/or individuals with type 1 or type 2 diabetes
Exclusion
- Have a hemoglobin A1c (HbA1c) \>9.5%
- New York Heart Association (NYHA) class III or IV congestive heart failure
- History of either a transient ischemic stroke or ischemic stroke \<30 days
- History of acute coronary syndrome (ACS) \<30 days
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
366 Patients enrolled
Trial Details
Trial ID
NCT02227784
Start Date
October 1 2014
End Date
December 1 2015
Last Update
October 8 2019
Active Locations (64)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Center Research, LLC
Huntsville, Alabama, United States, 35801
2
Desert Clinical Research
Mesa, Arizona, United States, 85213
3
Central Phoenix Med Clinic LLC
Phoenix, Arizona, United States, 85020
4
Advanced Clinical Research
Carmichael, California, United States, 95608